Headlands Technologies’s Xenon Pharmaceuticals XENE Stock Holding History

Headlands Technologies’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.76M	Buy	29,194 +23,074	+377%	+$1.28M	0.19%	133
2026 Q1	$356K	Buy	+6,120	New	+$282K	0.04%	452
2024 Q1	–	Sell	-23	Closed	-$1.06K	–	1588
2023 Q4	$1.06K	Sell	23 -4	-15%	-$141	﹤0.01%	898
2023 Q3	$922	Buy	+27	New	+$1.01K	﹤0.01%	860

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Headlands Technologies's XENE Position: Q2 2026 in Review

Headlands Technologies increased its Xenon Pharmaceuticals (XENE) stake by 377% in Q2 2026, buying an estimated $1.28M and bringing the position to 29,194 shares worth $1.76M. The position accounts for 0.19% of the portfolio, ranked #133.

Headlands Technologies first reported a position in XENE in Q3 2023 and has held it in 4 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Headlands Technologies held 29,194 shares of Xenon Pharmaceuticals worth $1.76M as of Q2 2026.
Headlands Technologies bought 23,074 Xenon Pharmaceuticals shares in Q2 2026, an estimated $1.28M.
Xenon Pharmaceuticals made up 0.19% of Headlands Technologies's portfolio in Q2 2026, its #133 holding.
Headlands Technologies first reported a position in Xenon Pharmaceuticals in Q3 2023 and has held it in 4 quarters since.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.